Amicus Therapeutics’ (FOLD) “Hold” Rating Reiterated at Needham & Company LLC

Amicus Therapeutics (NASDAQ:FOLDGet Free Report)‘s stock had its “hold” rating restated by analysts at Needham & Company LLC in a report issued on Monday,Benzinga reports.

A number of other equities research analysts have also recently commented on FOLD. Guggenheim increased their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Morgan Stanley restated an “equal weight” rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. JPMorgan Chase & Co. increased their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Finally, Bank of America boosted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.88.

Get Our Latest Stock Analysis on Amicus Therapeutics

Amicus Therapeutics Stock Performance

Shares of NASDAQ:FOLD opened at $9.21 on Monday. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics has a 1 year low of $8.78 and a 1 year high of $14.03. The firm has a market capitalization of $2.75 billion, a PE ratio of -27.09 and a beta of 0.62. The business’s 50 day moving average price is $9.86 and its 200-day moving average price is $10.54.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 22,901 shares of company stock worth $259,863 over the last quarter. 2.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Amicus Therapeutics

A number of hedge funds have recently made changes to their positions in FOLD. Park Avenue Securities LLC purchased a new stake in Amicus Therapeutics in the fourth quarter valued at approximately $123,000. Diversified Trust Co grew its stake in shares of Amicus Therapeutics by 9.7% in the fourth quarter. Diversified Trust Co now owns 81,758 shares of the biopharmaceutical company’s stock valued at $770,000 after buying an additional 7,257 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at $107,000. Old West Investment Management LLC lifted its stake in Amicus Therapeutics by 617.2% during the 3rd quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock worth $3,636,000 after acquiring an additional 292,976 shares in the last quarter. Finally, Neo Ivy Capital Management purchased a new position in Amicus Therapeutics during the 3rd quarter valued at about $702,000.

About Amicus Therapeutics

(Get Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Read More

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.